Genome editing to model and reverse a prevalent mutation associated with myeloproliferative neoplasms

Myeloproliferative neoplasms (MPNs) cause the over-production of blood cells such as erythrocytes (polycythemia vera) or platelets (essential thrombocytosis). JAK2 V617F is the most prevalent somatic mutation in many MPNs, but previous modeling of this mutation in mice relied on transgenic overexpre...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2021-03, Vol.16 (3), p.e0247858-e0247858
Main Authors: Baik, Ron, Wyman, Stacia K, Kabir, Shaheen, Corn, Jacob E
Format: Article
Language:English
Subjects:
Biology
Biology and Life Sciences
Blood diseases
Bone marrow
Corn
CRISPR
Cytokines
Data analysis
Editing
Electroporation
Endonuclease
Genetic engineering
Genome editing
Genomes
Genomics
Hematology
Hematopoietic stem cell disorders
Human performance
Hyperplasia
Janus kinase 2
Kinases
Mutation
Neoplasms
Patients
Reagents
Research and Analysis Methods
Reviews
Transcription
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myeloproliferative neoplasms (MPNs) cause the over-production of blood cells such as erythrocytes (polycythemia vera) or platelets (essential thrombocytosis). JAK2 V617F is the most prevalent somatic mutation in many MPNs, but previous modeling of this mutation in mice relied on transgenic overexpression and resulted in diverse phenotypes that were in some cases attributed to expression level. CRISPR-Cas9 engineering offers new possibilities to model and potentially cure genetically encoded disorders via precise modification of the endogenous locus in primary cells. Here we develop "scarless" Cas9-based reagents to create and reverse the JAK2 V617F mutation in an immortalized human erythroid progenitor cell line (HUDEP-2), CD34+ adult human hematopoietic stem and progenitor cells (HSPCs), and immunophenotypic long-term hematopoietic stem cells (LT-HSCs). We find no overt in vitro increase in proliferation associated with an endogenous JAK2 V617F allele, but co-culture with wild type cells unmasks a competitive growth advantage provided by the mutation. Acquisition of the V617F allele also promotes terminal differentiation of erythroid progenitors, even in the absence of hematopoietic cytokine signaling. Taken together, these data are consistent with the gradually progressive manifestation of MPNs and reveals that endogenously acquired JAK2 V617F mutations may yield more subtle phenotypes as compared to transgenic overexpression models.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0247858